Addressing Cancer Treatment Shortages in Saudi Arabia: Results of a National Survey and Expert Panel Recommendations.
Journal
JCO global oncology
ISSN: 2687-8941
Titre abrégé: JCO Glob Oncol
Pays: United States
ID NLM: 101760170
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
entrez:
24
3
2020
pubmed:
24
3
2020
medline:
29
7
2021
Statut:
ppublish
Résumé
Cancer treatment shortages are complex and a persistent problem worldwide. Patients with cancer are most vulnerable to drug shortages, which provides opportunities to examine the extent of the challenge(s) facing Saudi Arabia and to provide recommendations toward mitigating the impact of cancer treatment shortages on patient outcomes. A qualitative methodologic approach was conducted in April 2019 using a validated questionnaire and structured panel discussion for data generation. Overall, 55 responses were received from practicing oncology health care professionals (26 pharmacists and 29 physicians). The annual average number of treated patients with cancer per institution was 640 (adults [n = 400] and pediatric [n = 240]). All respondents (100%) reported that cancer treatment shortages constitute a current problem in their center, with an average of 5 (range, 1-9) per month. The panelists recognized 2 fundamental points. First, the definition of cancer drug shortages should be standardized and recognized at the national level. Second, the current system must be improved to ensure proper and efficient use of the current resources. On that basis, the panelists developed 9 recommendations for action. Cancer drug shortage is a significant problem in all health centers in Saudi Arabia. This study presents challenges that should be addressed at the national level and essential consensus recommendations for a coordinated action developed by a panel of experts to tackle the current national problem of cancer treatment shortages. Implementing these recommendations will provide a blueprint for management of national drug shortages in general and cancer treatment shortages in particular.
Identifiants
pubmed: 32202921
doi: 10.1200/JGO.19.00230
pmc: PMC7113076
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
476-485Références
J Pediatr Pharmacol Ther. 2015 Mar-Apr;20(2):149-52
pubmed: 25964733
PLoS One. 2017 Jun 5;12(6):e0178429
pubmed: 28582409
S D Med. 2011 Jan;64(1):14-5
pubmed: 21337920
Leuk Lymphoma. 2013 Oct;54(10):2231-5
pubmed: 23383599
Prev Med. 2013 Aug;57(2):146
pubmed: 23648524
Ann Saudi Med. 2017 Sep-Oct;37(5):375-385
pubmed: 28988252
Saudi Pharm J. 2018 Nov;26(7):947-951
pubmed: 30416350
Hosp Pharm. 2016 May;51(5):370-5
pubmed: 27303090
P T. 2011 Nov;36(11):740-57
pubmed: 22346307
J Crit Care. 2017 Oct;41:283-288
pubmed: 28622641
P T. 2011 May;36(5):242-302
pubmed: 21785536
Am J Health Syst Pharm. 2013 Apr 1;70(7):609-17
pubmed: 23515514
Mayo Clin Proc. 2014 Mar;89(3):361-73
pubmed: 24582195
J Natl Compr Canc Netw. 2011 Aug 1;9(8):815-9
pubmed: 21900216
J Glob Oncol. 2019 Apr;5:1-11
pubmed: 30969808
Fed Pract. 2018 Jan;35(1):24-31
pubmed: 30766319
Eur J Hosp Pharm. 2019 Mar;26(2):60-65
pubmed: 31157101
Global Health. 2016 Jun 08;12(1):31
pubmed: 27267898
J Clin Oncol. 2012 Mar 1;30(7):692-4
pubmed: 22291078
Risk Manag Healthc Policy. 2019 Jul 09;12:115-121
pubmed: 31372073
N Engl J Med. 2012 Dec 27;367(26):2461-3
pubmed: 23268661
BMC Health Serv Res. 2014 Sep 26;14:438
pubmed: 25257912
Am J Health Syst Pharm. 2009 Aug 1;66(15):1399-406
pubmed: 19635779
Eur Rev Med Pharmacol Sci. 2012 Jan;16(1):138-9
pubmed: 22338561
Pediatr Blood Cancer. 2015 Jun;62(6):940-4
pubmed: 25704486
Australas Med J. 2013 Nov 30;6(11):556-9
pubmed: 24348871